Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122136693 | 12213669 | 3 | F | 20160809 | 20160328 | 20160817 | EXP | US-PFIZER INC-2016162659 | PFIZER | 81.00 | YR | F | Y | 51.70000 | KG | 20160817 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122136693 | 12213669 | 1 | PS | SULFASALAZINE. | SULFASALAZINE | 1 | Oral | 1000 MG, 2X/DAY (500 MG 2 TABS 2X PER DAY) | 7073 | 1000 | MG | TABLET | BID | ||||||
| 122136693 | 12213669 | 2 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | UNK | 7073 | TABLET | ||||||||||
| 122136693 | 12213669 | 3 | SS | HYDROXYCHLOROQUINE | HYDROXYCHLOROQUINE | 1 | UNK | N | 0 | ||||||||||
| 122136693 | 12213669 | 4 | C | COMBIGAN | BRIMONIDINE TARTRATETIMOLOL MALEATE | 1 | Ophthalmic | BRIMONIDINE TARTRATE: 0.2%, TIMOLOL MALEATE: 0.5 % | 0 | ||||||||||
| 122136693 | 12213669 | 5 | C | DORZOLAMIDE HCL | DORZOLAMIDE HYDROCHLORIDE | 1 | Ophthalmic | 2 %, UNK | 0 | 2 | PCT | ||||||||
| 122136693 | 12213669 | 6 | C | LEFLUNOMIDE. | LEFLUNOMIDE | 1 | Oral | 20 MG, UNK | 0 | 20 | MG | TABLET | |||||||
| 122136693 | 12213669 | 7 | C | LOSARTAN POTASSIUM. | LOSARTAN POTASSIUM | 1 | Oral | 25 MG, UNK | 0 | 25 | MG | TABLET | |||||||
| 122136693 | 12213669 | 8 | C | MONTELUKAST SODIUM. | MONTELUKAST SODIUM | 1 | Oral | 10 MG, UNK | 0 | 10 | MG | TABLET | |||||||
| 122136693 | 12213669 | 9 | C | TRAZODONE HYDROCHLORIDE. | TRAZODONE HYDROCHLORIDE | 1 | Oral | 50 MG, UNK | 0 | 50 | MG | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122136693 | 12213669 | 1 | Rheumatoid arthritis |
| 122136693 | 12213669 | 3 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122136693 | 12213669 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122136693 | 12213669 | Activities of daily living impaired | |
| 122136693 | 12213669 | Arthralgia | |
| 122136693 | 12213669 | Arthropathy | |
| 122136693 | 12213669 | Coronary artery disease | |
| 122136693 | 12213669 | Deformity | |
| 122136693 | 12213669 | Disease progression | |
| 122136693 | 12213669 | Dry eye | |
| 122136693 | 12213669 | Essential hypertension | |
| 122136693 | 12213669 | Gait disturbance | |
| 122136693 | 12213669 | Sjogren's syndrome | |
| 122136693 | 12213669 | Tremor |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122136693 | 12213669 | 1 | 20151119 | 0 | ||
| 122136693 | 12213669 | 4 | 20140701 | 0 | ||
| 122136693 | 12213669 | 5 | 20141210 | 0 | ||
| 122136693 | 12213669 | 6 | 20150727 | 0 | ||
| 122136693 | 12213669 | 7 | 20141004 | 0 | ||
| 122136693 | 12213669 | 8 | 20151027 | 0 | ||
| 122136693 | 12213669 | 9 | 20150611 | 0 |